Calidi Biotherapeutics, Inc.
CLDI
$1.56
-$0.18-10.35%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.99M | 11.53M | 12.90M | 16.55M | 17.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.98M | 20.09M | 21.78M | 27.57M | 29.57M |
| Operating Income | -19.98M | -20.09M | -21.78M | -27.57M | -29.57M |
| Income Before Tax | -20.03M | -20.03M | -22.20M | -26.28M | -23.23M |
| Income Tax Expenses | 9.00K | 13.00K | 14.00K | 8.00K | 20.00K |
| Earnings from Continuing Operations | -20.04 | -20.05 | -22.21 | -26.29 | -23.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 188.00K | 142.00K | 66.00K | 15.00K | -- |
| Net Income | -19.85M | -19.90M | -22.14M | -26.28M | -23.25M |
| EBIT | -19.98M | -20.09M | -21.78M | -27.57M | -29.57M |
| EBITDA | -18.98M | -19.15M | -20.82M | -26.62M | -28.63M |
| EPS Basic | -21.47 | -22.40 | -44.58 | -69.08 | -78.30 |
| Normalized Basic EPS | -13.35 | -16.30 | -30.17 | -45.50 | -48.75 |
| EPS Diluted | -21.47 | -22.40 | -44.58 | -69.08 | -78.30 |
| Normalized Diluted EPS | -13.35 | -16.30 | -30.17 | -45.50 | -48.75 |
| Average Basic Shares Outstanding | 4.87M | 4.63M | 2.67M | 1.69M | 1.16M |
| Average Diluted Shares Outstanding | 4.87M | 4.63M | 2.67M | 1.69M | 1.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |